- Home
- MYGN vs SEAT Comparison
MYGN vs SEAT Comparison
Compare MYGN & SEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- SEAT
- Stock Information
- Founded
- MYGN 1991
- SEAT 2001
- Country
- MYGN United States
- SEAT United States
- Employees
- MYGN N/A
- SEAT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SEAT Industrial Machinery/Components
- Sector
- MYGN Health Care
- SEAT Industrials
- Exchange
- MYGN Nasdaq
- SEAT Nasdaq
- Market Cap
- MYGN 423.1M
- SEAT 366.2M
- IPO Year
- MYGN 1995
- SEAT N/A
- Fundamental
- Price
- MYGN $6.02
- SEAT $16.98
- Analyst Decision
- MYGN Hold
- SEAT Buy
- Analyst Count
- MYGN 13
- SEAT 11
- Target Price
- MYGN $13.50
- SEAT $68.00
- AVG Volume (30 Days)
- MYGN 2.4M
- SEAT 274.4K
- Earning Date
- MYGN 08-05-2025
- SEAT 08-05-2025
- Dividend Yield
- MYGN N/A
- SEAT N/A
- EPS Growth
- MYGN N/A
- SEAT N/A
- EPS
- MYGN N/A
- SEAT N/A
- Revenue
- MYGN $832,900,000.00
- SEAT $694,007,000.00
- Revenue This Year
- MYGN N/A
- SEAT N/A
- Revenue Next Year
- MYGN $6.64
- SEAT $4.42
- P/E Ratio
- MYGN N/A
- SEAT N/A
- Revenue Growth
- MYGN 3.83
- SEAT N/A
- 52 Week Low
- MYGN $3.76
- SEAT $15.13
- 52 Week High
- MYGN $29.30
- SEAT $100.00
- Technical
- Relative Strength Index (RSI)
- MYGN 62.34
- SEAT 32.42
- Support Level
- MYGN $5.23
- SEAT $15.13
- Resistance Level
- MYGN $6.07
- SEAT $18.53
- Average True Range (ATR)
- MYGN 0.39
- SEAT 2.95
- MACD
- MYGN 0.05
- SEAT -0.03
- Stochastic Oscillator
- MYGN 81.27
- SEAT 9.33
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.